03/23/2026
Psychiatry may be quietly shifting away from monoamines and toward something much deeper: neuroplasticity.
For decades psychiatry framed depression primarily through the lens of monoamines. SSRIs, SNRIs, and dopamine modulation dominated the conversation, and for many people those medications still work well. But the past decade has forced the field to reconsider whether we have been focusing on the wrong level of the system.
Increasingly, the evidence suggests that many effective treatments converge on something deeper: neuroplasticity.
Ketamine and esketamine accelerated this conversation by demonstrating that meaningful antidepressant effects could occur within hours rather than weeks. The emerging psychoplastogen literature raised an even more provocative question: if structural and functional plasticity is the true therapeutic driver, do we actually need the psychedelic experience to achieve it?
That question led me to a molecule I have been watching for quite some time: osavampator.
Unlike ketamine, which indirectly increases AMPA signaling through NMDA antagonism, osavampator works directly as a positive allosteric modulator of the AMPA receptor. In other words, it attempts to engage the same plasticity cascade from a different entry point.
What makes this particularly interesting from a clinical standpoint is the potential practicality. Running a Spravato treatment center reinforces every day that while these treatments can be extremely effective, they also require infrastructure. Monitoring, chair time, scheduling, staff, and a controlled clinical environment all become part of the therapeutic equation.
An orally administered AMPA modulator that engages plasticity pathways without dissociation or sedation would represent a very different implementation model if the signal holds.
Early Phase 2 data from the SAVITRI trial have generated attention, with effect sizes approaching 0.7 and remission rates nearing 50 percent by eight weeks in adjunctive treatment resistant depression. Whether those results replicate in Phase 3 remains to be seen, but mechanistically the compound sits directly in the middle of the broader shift psychiatry appears to be undergoing.
We may be moving away from receptor occupancy as our dominant framework and toward something more fundamental: circuit modulation and network plasticity.
Edition 10 of The Neuropsychiatry Brief explores this emerging AMPA story and why it may represent another piece of the larger plasticity puzzle.
If the future of antidepressant treatment is about helping the brain reorganize itself rather than simply nudging neurotransmitters, this is a development worth watching.
If you enjoy these discussions, you can subscribe to The Neuropsychiatry Brief directly on LinkedIn.
If you have followed this newsletter over the past several editions, you have probably noticed that a recurring theme keeps appearing beneath many of the mechanisms we discuss. Whether we are talking about ketamine, psychoplastogens, neuromodulation, or emerging serotonergic compounds, the conversat